"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

With Axtria Ignite 2025 just around the corner, attention turns to how the life sciences industry is preparing for the next ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...